hotspot -WSS

hotspot

author：focus 2025-10-02 18:48:45 - browse：237

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： First Opinion on colorectal cancer screening: letter and response

focus

WSS

Four alarming medical procedures we’re glad history forgot

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

Study: Hearing aids may slow cognitive decline in those at risk

A look at other Americans who have crossed into North Korea over the years

Lack of darker skin in textbooks, journals harms patients of color

Bird flu in dairy cattle: New measures to control spread to humans

knowledge

hotspot

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Multiple sclerosis has subtypes with different best treatments: study

Sports medicine is finally prioritizing gender equality

Robert Kennedy Jr.'s presidential campaign attracts GOP

After affirmative action ruling, medical educators look to 'holistic review'

More hospitals are billing patients as online messages surge

Cancer drug shortages should be causing more outrage

Gut bacteria may contribute to kidney autoimmunity, study finds

Peter Hotez and the public health issue of online harassment

Twill hunts for pharma partner to market its depression app

hotspot

Four alarming medical procedures we’re glad history forgot

Robert Kennedy Jr.'s presidential campaign attracts GOP

Scientific mystery highlights the blind spots in genomics databases

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Oral obesity drug from Viking Therapeutics hits key early target

Biden administration sends mixed signals on US soldier who crossed into North Korea

leisure time

focus

Wikipedia

hotspot